225 related articles for article (PubMed ID: 28838275)
41. Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions.
Huang Z; Li L; Wang J
Dig Dis Sci; 2007 Sep; 52(9):2287-91. PubMed ID: 17410438
[TBL] [Abstract][Full Text] [Related]
42. Detection of 14-3-3 sigma (σ) promoter methylation as a noninvasive biomarker using blood samples for breast cancer diagnosis.
Ye M; Huang T; Ying Y; Li J; Yang P; Ni C; Zhou C; Chen S
Oncotarget; 2017 Feb; 8(6):9230-9242. PubMed ID: 27999208
[TBL] [Abstract][Full Text] [Related]
43. Sensitivity of a blood ctDNA-based multimodal test for the detection of advanced colorectal neoplasms.
Brenner H; Niedermaier T; Hoffmeister M
Ann Oncol; 2024 May; 35(5):476-477. PubMed ID: 38311210
[No Abstract] [Full Text] [Related]
44. Circulating Cell-Free DNA and Cancer Therapy Monitoring: Methods and Potential.
Gahan PB
Methods Mol Biol; 2019; 1909():31-46. PubMed ID: 30580421
[TBL] [Abstract][Full Text] [Related]
45. Tumor-specific methylations in circulating cell-free DNA as clinically applicable markers with potential to substitute mutational analyses.
Andersen RF
Expert Rev Mol Diagn; 2018 Dec; 18(12):1011-1019. PubMed ID: 30411633
[No Abstract] [Full Text] [Related]
46. Establishment and characterization of cell lines from chromosomal instable colorectal cancer.
Maletzki C; Gock M; Randow M; Klar E; Huehns M; Prall F; Linnebacher M
World J Gastroenterol; 2015 Jan; 21(1):164-76. PubMed ID: 25574089
[TBL] [Abstract][Full Text] [Related]
47. Clinical and molecular features of young-onset colorectal cancer.
Ballester V; Rashtak S; Boardman L
World J Gastroenterol; 2016 Feb; 22(5):1736-44. PubMed ID: 26855533
[TBL] [Abstract][Full Text] [Related]
48. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH
Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418
[TBL] [Abstract][Full Text] [Related]
49. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
[TBL] [Abstract][Full Text] [Related]
50. Epigenome-wide discovery and evaluation of leukocyte DNA methylation markers for the detection of colorectal cancer in a screening setting.
Heiss JA; Brenner H
Clin Epigenetics; 2017; 9():24. PubMed ID: 28270869
[TBL] [Abstract][Full Text] [Related]
51. Circulating tumor DNA as a marker of minimal residual disease in colorectal cancer.
Kopetz S
Clin Adv Hematol Oncol; 2020 Dec; 18(12):791-792. PubMed ID: 33406055
[No Abstract] [Full Text] [Related]
52. Methylation associated transcriptional repression of ELOVL5 in novel colorectal cancer cell lines.
Boot A; Oosting J; van Eendenburg JDH; Kuppen PJK; Morreau H; van Wezel T
PLoS One; 2017; 12(9):e0184900. PubMed ID: 28931069
[TBL] [Abstract][Full Text] [Related]
53. Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer.
He T; Zhang M; Zheng R; Zheng S; Linghu E; Herman JG; Guo M
Epigenomics; 2017 Jun; 9(6):849-862. PubMed ID: 28403629
[TBL] [Abstract][Full Text] [Related]
54. Genetic and molecular origins of colorectal Cancer among the Iranians: an update.
Abbaszadegan MR; Moghbeli M
Diagn Pathol; 2018 Dec; 13(1):97. PubMed ID: 30579343
[TBL] [Abstract][Full Text] [Related]
55. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances.
Lech G; Słotwiński R; Słodkowski M; Krasnodębski IW
World J Gastroenterol; 2016 Feb; 22(5):1745-55. PubMed ID: 26855534
[TBL] [Abstract][Full Text] [Related]
56. Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer.
Ichimura N; Shinjo K; An B; Shimizu Y; Yamao K; Ohka F; Katsushima K; Hatanaka A; Tojo M; Yamamoto E; Suzuki H; Ueda M; Kondo Y
Cancer Prev Res (Phila); 2015 Aug; 8(8):702-11. PubMed ID: 26063725
[TBL] [Abstract][Full Text] [Related]
57. Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden.
Bhangu JS; Taghizadeh H; Braunschmid T; Bachleitner-Hofmann T; Mannhalter C
Surg Oncol; 2017 Dec; 26(4):395-401. PubMed ID: 29113658
[TBL] [Abstract][Full Text] [Related]
58. Predicting disease-free survival in colorectal cancer by circulating tumor DNA methylation markers.
Yang X; Wen X; Guo Q; Zhang Y; Liang Z; Wu Q; Li Z; Ruan W; Ye Z; Wang H; Chen Z; Fan JB; Lan P; Liu H; Wu X
Clin Epigenetics; 2022 Dec; 14(1):160. PubMed ID: 36457093
[TBL] [Abstract][Full Text] [Related]
59. Commonality and differences of methylation signatures in the plasma of patients with pancreatic cancer and colorectal cancer.
Melson J; Li Y; Cassinotti E; Melnikov A; Boni L; Ai J; Greenspan M; Mobarhan S; Levenson V; Deng Y
Int J Cancer; 2014 Jun; 134(11):2656-62. PubMed ID: 24288256
[TBL] [Abstract][Full Text] [Related]
60. Epigenetic biomarkers of colorectal cancer: Focus on DNA methylation.
Coppedè F
Cancer Lett; 2014 Jan; 342(2):238-47. PubMed ID: 22202641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
